cagrisema semaglutide cagrilintide phase 3 results 2024 2025 Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1 Novo's CagriSema loses phase 3

Kelly, MD As gastroenterologists, we treat a number of conditions that are caused or worsened by obesity

A pooled analysis of SUSTAIN trials found that semaglutide 1 mg reduced triglycerides by 12.4% and total cholesterol by 4.6% from baseline, independent of background statin use [10]

These drugs are FDA-approved for treating Type 2 diabetes and obesity, with additional benefits for patients with heart disease or sleep apnea

That chain is what connects to the serious outcomes it names, including acute kidney injury and pancreatitis

The corresponding study-specific crude advantage ratios and 95% confidence intervals for CRC risk were calculated